ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$25.87
-0.68 (-2.56%)
▼
5d:
+4.15%
30d:
+2.66%
90d:
+15.23%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 04, 2026
1d
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACAD shows positive signals but monitor for confirmation. Market pricing in 3.3% growth. Moderate conviction.
💡 BUY OPPORTUNITY: ACAD shows positive signals but monitor for confirmation. Market pricing in 3.3% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$41.61
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$25.83
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $25.87, which is considered slightly high relative to its 30-day fair value range of $24.21 to $26.33. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.3) compared to its historical average (27.4). At these levels, the market is pricing in 3.3% annual earnings growth.
Technical Outlook: Technically, ACAD is in a strong uptrend. The price is approaching resistance at $26.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.95 (+27.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACAD is in a strong uptrend. The price is approaching resistance at $26.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.95 (+27.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$24.21 -
$26.33
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.6%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.4% below Wall St target ($32.95)
- BULLISH: Expecting earnings turnaround to 3.3% growth with 9.7% revenue growth
Trading Range Analysis
30-Day Trading Range
$24.21 -
$26.33
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$24.23
Resistance Level
$26.58
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.27
Wall Street Target
$32.95
(+27.4%)
Revenue Growth (YoY)
9.7%
Earnings Growth (YoY)
-81.8%
Profit Margin
34.3%
Valuation Premium vs History
+3.3% premium
PE vs Historical
30.3 vs 27.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.3%
(market-implied from PE analysis)
1-Year Target
$26.72
(+3%)
2-Year Target
$27.61
(+7%)
3-Year Target
$28.52
(+10%)
3-Yr Target (if PE normalizes)
(PE: 30→27)
PE COMPRESSION
$25.81
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.3, Growth: 133.1%)
$87.31
(+238%)
Base:
(SPY PE: 20.7, Growth: 133.1%)
$59.79
(+131%)
Bear:
(PE: 17.6, Growth: 133.1%)
$50.82
(+97%)
📈
Valuation based on Current Earnings
Trailing PE: 11.91 | Current EPS (TTM): $2.23
Bull Case
$14.60
(-44%)
Analyst growth -50.0%, PE expands to 13.1
Base Case
$13.27
(-49%)
Market implied -50.0%, PE stable at 11.9
Bear Case
$18.05
(-30%)
Severe decline -20.0%, PE contracts to 10.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 02, 2026 11:50 AM ET
Data refreshes hourly during market hours. Next update: 12:50 PM
Data refreshes hourly during market hours. Next update: 12:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Jennifer J Rhodes
SELL
6950 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
